Supernus Pharmaceuticals annual operating expenses
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Operating Expenses Growth & History (SUPN)
Supernus Pharmaceuticals's operating expenses was $706.7M for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $706.7M | $204.4M | +40.70% |
| 2024 | 2024-12-31 | $502.2M | −$26.8M | −5.06% |
| 2023 | 2023-12-31 | $529.0M | −$4.9M | −0.91% |
| 2022 | 2022-12-31 | $533.9M | $115.2M | +27.52% |
| 2021 | 2021-12-31 | $418.7M | $124.4M | +42.29% |
| 2020 | 2020-12-31 | $294.2M | $66.7M | +29.32% |
| 2019 | 2019-12-31 | $227.5M | −$21.6M | −8.66% |
| 2018 | 2018-12-31 | $249.1M | $61.6M | +32.86% |
| 2017 | 2017-12-31 | $187.5M | $38.7M | +26.00% |
| 2016 | 2016-12-31 | $148.8M | $30.6M | +25.89% |
| 2015 | 2015-12-31 | $118.2M | $26.0M | +28.20% |
| 2014 | 2014-12-31 | $92.2M | $19.4M | +26.58% |
| 2013 | 2013-12-31 | $72.8M | $29.2M | +66.87% |
| 2012 | 2012-12-31 | $43.6M | $5.1M | +13.21% |
| 2011 | 2011-12-31 | $38.6M | −$1.7M | −4.16% |
| 2010 | 2010-12-31 | $40.2M | — | — |
Supernus Pharmaceuticals quarterly operating expenses
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $243.4M | $106.9M | +78.30% |
| Q1 2026 | 2026-03-31 | $192.6M | $48.3M | +33.49% |
| Q4 2025 | 2025-12-31 | $192.5M | $65.8M | +51.99% |
| Q3 2025 | 2025-09-30 | $233.4M | $116.1M | +99.02% |
| Q2 2025 | 2025-06-30 | $136.5M | $8.6M | +6.76% |
| Q1 2025 | 2025-03-31 | $144.3M | $13.8M | +10.60% |
| Q4 2024 | 2024-12-31 | $126.7M | −$19.0M | −13.06% |
| Q3 2024 | 2024-09-30 | $117.3M | −$8.9M | −7.04% |
| Q2 2024 | 2024-06-30 | $127.8M | −$4.2M | −3.19% |
| Q1 2024 | 2024-03-31 | $130.5M | $5.4M | +4.28% |
| Q4 2023 | 2023-12-31 | $145.7M | $35.6M | +32.39% |
| Q3 2023 | 2023-09-30 | $126.1M | −$26.9M | −17.55% |
| Q2 2023 | 2023-06-30 | $132.1M | −$6.2M | −4.48% |
| Q1 2023 | 2023-03-31 | $125.1M | −$7.5M | −5.64% |
| Q4 2022 | 2022-12-31 | $110.0M | −$25.9M | −19.06% |
| Q3 2022 | 2022-09-30 | $153.0M | $55.2M | +56.48% |
| Q2 2022 | 2022-06-30 | $138.2M | $56.1M | +68.21% |
| Q1 2022 | 2022-03-31 | $132.6M | $29.8M | +29.04% |
| Q4 2021 | 2021-12-31 | $136.0M | $53.9M | +65.75% |
| Q3 2021 | 2021-09-30 | $97.8M | $20.2M | +25.99% |
| Q2 2021 | 2021-06-30 | $82.2M | $9.4M | +12.90% |
| Q1 2021 | 2021-03-31 | $102.8M | $41.0M | +66.25% |
| Q4 2020 | 2020-12-31 | $82.0M | $22.4M | +37.56% |
| Q3 2020 | 2020-09-30 | $77.6M | $20.0M | +34.75% |
| Q2 2020 | 2020-06-30 | $72.8M | $14.7M | +25.39% |
| Q1 2020 | 2020-03-31 | $61.8M | $5.5M | +9.67% |
| Q4 2019 | 2019-12-31 | $59.6M | −$16.4M | −21.62% |
| Q3 2019 | 2019-09-30 | $57.6M | −$3.7M | −6.07% |
| Q2 2019 | 2019-06-30 | $58.1M | −$2.1M | −3.46% |
| Q1 2019 | 2019-03-31 | $56.4M | $605,000 | +1.09% |
| Q4 2018 | 2018-12-31 | $76.1M | $22.0M | +40.65% |
| Q3 2018 | 2018-09-30 | $61.3M | $7.5M | +13.96% |
| Q2 2018 | 2018-06-30 | $60.1M | $14.2M | +31.01% |
| Q1 2018 | 2018-03-31 | $55.8M | $17.9M | +47.35% |
| Q4 2017 | 2017-12-31 | $54.1M | $8.0M | +17.39% |
| Q3 2017 | 2017-09-30 | $53.8M | $20.3M | +60.41% |
| Q2 2017 | 2017-06-30 | $45.9M | $8.7M | +23.29% |
| Q1 2017 | 2017-03-31 | $37.8M | $2.1M | +5.93% |
| Q4 2016 | 2016-12-31 | $46.1M | $10.3M | +28.69% |
| Q3 2016 | 2016-09-30 | $33.5M | $1.5M | +4.73% |
| Q2 2016 | 2016-06-30 | $37.2M | $7.2M | +23.80% |
| Q1 2016 | 2016-03-31 | $35.7M | $12.6M | +54.73% |
| Q4 2015 | 2015-12-31 | $35.8M | $9.7M | +37.13% |
| Q3 2015 | 2015-09-30 | $32.0M | $9.9M | +44.91% |
| Q2 2015 | 2015-06-30 | $30.1M | $5.8M | +23.97% |
| Q1 2015 | 2015-03-31 | $23.1M | $1.1M | +4.89% |
| Q4 2014 | 2014-12-31 | $26.1M | $4.4M | +20.38% |
| Q3 2014 | 2014-09-30 | $22.1M | $3.7M | +20.13% |
| Q2 2014 | 2014-06-30 | $24.3M | $8.5M | +53.96% |
| Q1 2014 | 2014-03-31 | $22.0M | $4.0M | +21.90% |
| Q4 2013 | 2013-12-31 | $21.7M | $7.9M | +56.79% |
| Q3 2013 | 2013-09-30 | $18.4M | $6.0M | +48.61% |
| Q2 2013 | 2013-06-30 | $15.8M | $6.4M | +68.55% |
| Q1 2013 | 2013-03-31 | $18.1M | $10.0M | +123.29% |
| Q4 2012 | 2012-12-31 | $13.8M | $3.5M | +34.51% |
| Q3 2012 | 2012-09-30 | $12.4M | $2.5M | +24.73% |
| Q2 2012 | 2012-06-30 | $9.3M | $202,000 | +2.21% |
| Q1 2012 | 2012-03-31 | $8.1M | — | — |
| Q4 2011 | 2011-12-31 | $10.3M | — | — |
| Q3 2011 | 2011-09-30 | $9.9M | — | — |
| Q2 2011 | 2011-06-30 | $9.1M | — | — |
Supernus Pharmaceuticals operating expenses trends
Over the last five fiscal years, Supernus Pharmaceuticals's operating expenses increased from $294.2M to $706.7M, a change of $412.4M. The latest reported quarter, Q2 2026, shows $243.4M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
